{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:50:58Z","timestamp":1791989458373,"version":"4.4.0"},"reference-count":116,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","doi-asserted-by":"publisher","award":["2R01DK107451-05"],"award-info":[{"award-number":["2R01DK107451-05"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","doi-asserted-by":"publisher","award":["1R01CA230561-01A1"],"award-info":[{"award-number":["1R01CA230561-01A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","doi-asserted-by":"publisher","award":["1R01CA240004-01"],"award-info":[{"award-number":["1R01CA240004-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","doi-asserted-by":"publisher","award":["1R01CA244993-01"],"award-info":[{"award-number":["1R01CA244993-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["2R01DK107451-05"],"award-info":[{"award-number":["2R01DK107451-05"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["1R01CA230561-01A1"],"award-info":[{"award-number":["1R01CA230561-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["1R01CA240004-01"],"award-info":[{"award-number":["1R01CA240004-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["1R01CA244993-01"],"award-info":[{"award-number":["1R01CA244993-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) arises from hepatocytes and accounts for 90% of primary liver cancer. According to Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2020, globally HCC is the sixth most common cancer and the third most common cause of cancer-related deaths. Reasons for HCC prognosis remaining dismal are that HCC is asymptomatic in its early stages, leading to late diagnosis, and it is markedly resistant to conventional chemo- and radiotherapy. Liver transplantation is the treatment of choice in early stages, while surgical resection, radiofrequency ablation (RFA) and trans arterial chemoembolization (TACE) are Food and Drug Administration (FDA)-approved treatments for advanced HCC. Additional first line therapy for advanced HCC includes broad-spectrum tyrosine kinase inhibitors (TKIs), such as sorafenib and lenvatinib, as well as a combination of immunotherapy and anti-angiogenesis therapy, namely atezolizumab and bevacizumab. However, these strategies provide nominal extension in the survival curve, cause broad spectrum toxic side effects, and patients eventually develop therapy resistance. Some common mutations in HCC, such as in telomerase reverse transcriptase (TERT), catenin beta 1 (CTNNB1) and tumor protein p53 (TP53) genes, are still considered to be undruggable. In this context, identification of appropriate gene targets and specific gene delivery approaches create the potential of gene- and immune-based therapies for the safe and effective treatment of HCC. This review elaborates on the current status of HCC treatment by focusing on potential gene targets and advanced techniques, such as oncolytic viral vectors, nanoparticles, chimeric antigen receptor (CAR)-T cells, immunotherapy, and clustered regularly interspaced short palindromic repeats\/CRISPR-associated protein 9 (CRISPR\/Cas9), and describes future prospects in HCC treatment.<\/jats:p>","DOI":"10.3390\/cancers14112798","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T09:42:32Z","timestamp":1654335752000},"page":"2798","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":312,"title":["Emerging Therapies for Hepatocellular Carcinoma (HCC)"],"prefix":"10.3390","volume":"14","author":[{"given":"Eesha","family":"Chakraborty","sequence":"first","affiliation":[{"name":"C. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-2323","authenticated-orcid":false,"given":"Devanand","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Department of Human and Molecular Genetics, Massey Cancer Center, VCU Institute of Molecular Medicine (VIMM), Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1007\/s10620-019-05604-8","article-title":"Role of liver stiffness measurement in predicting HCC occurrence in direct-acting antivirals setting: A real-life experience","volume":"64","author":"Rinaldi","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rinaldi, L., Nevola, R., Franci, G., Perrella, A., Corvino, G., Marrone, A., Berretta, M., Morone, M.V., Galdiero, M., and Giordano, M. (2020). Risk of hepatocellular carcinoma after HCV clearance by direct-acting antivirals treatment predictive factors and role of epigenetics. Cancers, 12.","DOI":"10.3390\/cancers12061351"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2019.04.043","article-title":"Hepatocellular carcinoma incidence is decreasing among younger adults in the united states","volume":"18","author":"Rich","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"ref_5","first-page":"209","article-title":"Recent developments and therapeutic strategies against hepatocellular carcinoma","volume":"71","author":"Yarchoan","year":"2019","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40164-018-0109-6","article-title":"Emerging therapies in advanced hepatocellular carcinoma","volume":"7","author":"Medavaram","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-01968-w","article-title":"Advances in drug development for hepatocellular carcinoma: Clinical trials and potential therapeutic targets","volume":"40","author":"Luo","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hum.2013.2528","article-title":"The first journal on human gene therapy celebrates its 25th anniversary","volume":"25","author":"Wilson","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_9","first-page":"4711","article-title":"Delivery approaches of gene therapy in hepatocellular carcinoma","volume":"33","author":"Duan","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E92","DOI":"10.1208\/aapsj0901009","article-title":"Nonviral gene delivery: What we know and what is next","volume":"9","author":"Gao","year":"2007","journal-title":"AAPS J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.3892\/mmr.2015.4461","article-title":"Novel hydroxybutyl chitosan nanoparticles for siRNA delivery targeting tissue factor inhibits proliferation and induces apoptosis in human vascular smooth muscle cells","volume":"12","author":"Wan","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.15171\/apb.2019.023","article-title":"Current advances in chitosan nanoparticles based drug delivery and targeting","volume":"9","author":"Garg","year":"2019","journal-title":"Adv. Pharm. Bull."},{"key":"ref_14","first-page":"395","article-title":"Biological effects of irradiating hepatocellular carcinoma cells by internal exposure with 125i-labeled 5-iodo-2\u2032-deoxyuridine-chitosan drug loading nanoparticles","volume":"29","author":"Yang","year":"2014","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1080\/01635581.2020.1823436","article-title":"Ginger extract loaded into chitosan nanoparticles enhances cytotoxicity and reduces cardiotoxicity of doxorubicin in hepatocellular carcinoma in mice","volume":"73","author":"Mansour","year":"2021","journal-title":"Nutr. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1499-3872(15)60336-8","article-title":"Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells","volume":"14","author":"Zhong","year":"2015","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2174\/1871520616666160926111911","article-title":"Polo-like kinase 1-targeting chitosan nanoparticles suppress the progression of hepatocellular carcinoma","volume":"17","author":"Wang","year":"2017","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nano.2018.09.002","article-title":"Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms","volume":"15","author":"Zhang","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nair, A.B., Shah, J., Al-Dhubiab, B.E., Patel, S.S., Morsy, M.A., Patel, V., Chavda, V., Jacob, S., Sreeharsha, N., and Shinu, P. (2019). Development of asialoglycoprotein receptor-targeted nanoparticles for selective delivery of gemcitabine to hepatocellular carcinoma. Molecules, 24.","DOI":"10.3390\/molecules24244566"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejpb.2014.04.016","article-title":"Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice","volume":"88","author":"Nasr","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22149","DOI":"10.1038\/srep22149","article-title":"Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma","volume":"6","author":"Xue","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1166\/jbn.2014.2051","article-title":"Anti-tumor immune response of folate-conjugated chitosan nanoparticles containing the IP-10 gene in mice with hepatocellular carcinoma","volume":"10","author":"Lai","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.yexcr.2014.04.005","article-title":"Therapeutic efficacy of improved \u03b1-fetoprotein promoter-mediated tBid delivered by folate-PEI600-cyclodextrin nanopolymer vector in hepatocellular carcinoma","volume":"324","author":"Hu","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wu, Z., Xu, X.-L., Zhang, J.-Z., Mao, X.-H., Xie, M.-W., Cheng, Z.-L., Lu, L.-J., Duan, X.-H., Zhang, L.-M., and Shen, J. (2017). Magnetic cationic amylose nanoparticles used to deliver survivin-small interfering RNA for gene therapy of hepatocellular carcinoma in vitro. Nanomaterials, 7.","DOI":"10.3390\/nano7050110"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1471-2407-14-114","article-title":"Superparamagnetic iron oxide nanoparticles mediated 131I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice","volume":"14","author":"Chen","year":"2014","journal-title":"BMC Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/smll.201501985","article-title":"Iron-oxide-based nanovector for tumor targeted sirna delivery in an orthotopic hepatocellular carcinoma xenograft mouse model","volume":"12","author":"Wang","year":"2016","journal-title":"Small"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bae, Y., Song, S.J., Mun, J.Y., Ko, K.S., Han, J., and Choi, J.S. (2017). Apoptin gene delivery by the functionalized polyamidoamine (PAMAM) dendrimer modified with ornithine induces cell death of hepg2 cells. Polymers, 9.","DOI":"10.3390\/polym9060197"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1021\/acs.bioconjchem.5b00254","article-title":"Combination of nanoparticle-delivered siRNA for astrocyte elevated gene-1 (aeg-1) and all-trans retinoic acid (ATRA): An effective therapeutic strategy for hepatocellular carcinoma (HCC)","volume":"26","author":"Rajasekaran","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hep.29230","article-title":"A novel role of astrocyte elevated gene-1 (AEG-1) in regulating nonalcoholic steatohepatitis (NASH)","volume":"66","author":"Srivastava","year":"2017","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1039\/C9TX00103D","article-title":"Dendrimer-conjugated podophyllotoxin suppresses DENA-induced HCC progression by modulation of inflammatory and fibrogenic factors","volume":"8","author":"Sharma","year":"2019","journal-title":"Toxicol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kuruvilla, S.P., Tiruchinapally, G., Crouch, C., Elsayed, M.E.H., and Greve, J.M. (2017). Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181944"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omto.2021.04.004","article-title":"Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer","volume":"21","author":"Vaughan","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2174\/138945011795906570","article-title":"Lipid-based drug delivery systems for cancer treatment","volume":"12","author":"Arias","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_35","first-page":"GE01","article-title":"Non viral vectors in gene therapy\u2014An overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms4869","article-title":"Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice","volume":"5","author":"Bogorad","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-2571-4","article-title":"Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease","volume":"11","author":"Woitok","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.celrep.2015.02.027","article-title":"YAP Inhibition restores hepatocyte differentiation in advanced hcc, leading to tumor regression","volume":"10","author":"Fitamant","year":"2015","journal-title":"Cell Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s40425-018-0431-x","article-title":"Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma","volume":"6","author":"Lai","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2021.04.023","article-title":"Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma","volume":"334","author":"Witzigmann","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jconrel.2010.02.005","article-title":"Pegylated immuno-lipopolyplexes: A novel non-viral gene delivery system for liver cancer therapy","volume":"144","author":"Hu","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1021\/acs.biomac.8b00358","article-title":"Galactose derivative-modified nanoparticles for efficient siRNA delivery to hepatocellular carcinoma","volume":"19","author":"Huang","year":"2018","journal-title":"Biomacromolecules"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/hep.29513","article-title":"A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice","volume":"67","author":"Liu","year":"2018","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.nano.2013.05.007","article-title":"Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor","volume":"9","author":"Hsu","year":"2013","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"112420","DOI":"10.1016\/j.msec.2021.112420","article-title":"Surface tailored zein as a novel delivery system for hypericin: Application in photodynamic therapy","volume":"129","author":"Abdelsalam","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1061186X.2017.1289536","article-title":"PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma","volume":"25","author":"Ewais","year":"2017","journal-title":"J. Drug Target."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3748\/wjg.v22.i1.326","article-title":"Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma","volume":"22","author":"Wang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","article-title":"A simplified system for generating recombinant adenoviruses","volume":"95","author":"He","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/cgt.2010.40","article-title":"A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma","volume":"17","author":"Sangro","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/JVI.79.1.214-224.2005","article-title":"Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice","volume":"79","author":"Nakai","year":"2005","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13802","DOI":"10.1038\/s41598-018-30800-3","article-title":"AAV serotype 8-mediated liver specific GNMT expression delays progression of hepatocellular carcinoma and prevents carbon tetrachloride-induced liver damage","volume":"8","author":"Fang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","article-title":"Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model","volume":"137","author":"Kota","year":"2009","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00109-020-02034-2","article-title":"Evolving AAV-delivered therapeutics towards ultimate cures","volume":"99","author":"He","year":"2021","journal-title":"J. Mol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","article-title":"Lentiviral vectors in gene therapy: Their current status and future potential","volume":"58","author":"Escors","year":"2010","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1089\/104454902762053864","article-title":"Gene delivery using herpes simplex virus vectors","volume":"21","author":"Burton","year":"2002","journal-title":"DNA Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2012.02.016","article-title":"Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination","volume":"30","author":"Verheust","year":"2012","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/annonc\/mdw440","article-title":"Vectorized gene therapy of liver tumors: Proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine","volume":"28","author":"Husseini","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: A double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53- deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mantwill, K., Klein, F.G., Wang, D., Hindupur, S.V., Ehrenfeld, M., Holm, P.S., and Nawroth, R. (2021). Concepts in oncolytic adenovirus therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910522"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/OV.S59640","article-title":"The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)","volume":"4","author":"Breitbach","year":"2015","journal-title":"Oncolytic Virotherapy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1615817","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: A randomized multicenter phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1089\/hum.2020.114","article-title":"systematic characterization of the biodistribution of the oncolytic virus M1","volume":"31","author":"Cai","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Chouljenko, D., Ding, J., Lee, I.-F., Murad, Y., Bu, X., Liu, G., Delwar, Z., Sun, Y., Yu, S., and Samudio, I. (2020). induction of durable antitumor response by a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Biomedicines, 8.","DOI":"10.3390\/biomedicines8110484"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","article-title":"Talimogene laherparepvec: First global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/mt.2011.273","article-title":"Live and let die: A new suicide gene therapy moves to the clinic","volume":"20","author":"Morgan","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.radonc.2012.07.011","article-title":"Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo","volume":"105","author":"Sun","year":"2012","journal-title":"Radiother. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3748\/wjg.v10.i3.400","article-title":"Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer","volume":"10","author":"Wang","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.3389\/fmicb.2018.02375","article-title":"Discovery of bacterial deaminases that convert 5-fluoroisocytosine into 5-fluorouracil","volume":"9","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/hep.510310310","article-title":"Gene therapy of hepatocellular carcinomain vitro andin vivo in nude mice by adenoviral transfer of theescherichia coli purine nucleoside phosphorylase gene","volume":"31","author":"Mohr","year":"2000","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3892\/or.2013.2248","article-title":"Suicide gene therapy for hepatocellular carcinoma cells by survivin promoter-driven expression of the herpes simplex virus thymidine kinase gene","volume":"29","author":"Qu","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/cgt.2012.3","article-title":"Membrane-bound form of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy in a model of hepatocellular carcinoma","volume":"19","author":"Marukawa","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7150\/thno.13621","article-title":"Image-aided suicide gene therapy utilizing multifunctional htert-targeting adenovirus for clinical translation in hepatocellular carcinoma","volume":"6","author":"Kim","year":"2016","journal-title":"Theranostics"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/gt.2011.131","article-title":"Suicidal gene therapy in the effective control of primary human hepatocellular carcinoma as monitored by noninvasive bioimaging","volume":"19","author":"Sia","year":"2012","journal-title":"Gene Ther."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Li, J., Zhou, P., Li, L., Zhang, Y., Shao, Y., Tang, L., and Tian, S. (2016). Effects of cationic microbubble carrying CD\/TK double suicide gene and \u03b1V\u03b23 integrin antibody in human hepatocellular carcinoma HepG2 cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158592"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Zhang, B., Chen, M., Zhang, Y., Chen, W., Zhang, L., and Chen, L. (2018). An ultrasonic nanobubble-mediated PNP\/fludarabine suicide gene system: A new approach for the treatment of hepatocellular carcinoma. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196686"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using Crispr\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrg2749","article-title":"CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea","volume":"11","author":"Marraffini","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.18632\/oncotarget.27361","article-title":"CRISPR\/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma","volume":"10","author":"Zheng","year":"2019","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"57362","DOI":"10.1021\/acsami.0c17660","article-title":"Co-delivery of sorafenib and crispr\/cas9 based on targeted core\u2013shell hollow mesoporous organosilica nanoparticles for synergistic HCC therapy","volume":"12","author":"Zhang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jconrel.2021.03.030","article-title":"Charge-reversal nanocomolexes-based CRISPR\/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma","volume":"333","author":"Nie","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1016\/j.ygeno.2020.06.020","article-title":"lncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR\/Cas9 editing in hepatocellular carcinoma","volume":"112","author":"Ali","year":"2020","journal-title":"Genomics"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2001424","DOI":"10.1002\/advs.202001424","article-title":"A lactose-derived crispr\/cas9 delivery system for efficient genome editing in vivo to treat orthotopic hepatocellular carcinoma","volume":"7","author":"Qi","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10555-013-9461-5","article-title":"The promise of sonodynamic therapy","volume":"33","author":"Trendowski","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/acscentsci.1c01143","article-title":"Ultrasound-controlled crispr\/cas9 system augments sonodynamic therapy of hepatocellular carcinoma","volume":"7","author":"Yin","year":"2021","journal-title":"ACS Central Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2015.08.020","article-title":"Immunity, tolerance and autoimmunity in the liver: A comprehensive review","volume":"66","author":"Doherty","year":"2016","journal-title":"J. Autoimmun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory t cells correlate with cd8 t-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-12-3381","article-title":"higher frequencies of garp+ctla-4+foxp3+ t regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired t-cell functionality","volume":"73","author":"Kalathil","year":"2013","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","article-title":"Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade","volume":"175","author":"Maker","year":"2005","journal-title":"J. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/bs.acr.2020.12.001","article-title":"Systemic therapy of liver cancer","volume":"149","author":"Demir","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): An open-label, multicentre, phase 1b study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Shadbad, M.A., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., and Yue, S. (2020). Immune checkpoints and CAR-T cells: The pioneers in future cancer therapies?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218305"},{"key":"ref_108","first-page":"1","article-title":"Immunotherapy with CAR-modified T cells: Toxicities and overcoming strategies","volume":"2018","author":"Sun","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3389\/fimmu.2016.00690","article-title":"Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma","volume":"7","author":"Jiang","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Rochigneux, P., Chanez, B., De Rauglaudre, B., Mitry, E., Chabannon, C., and Gilabert, M. (2021). Adoptive cell therapy in hepatocellular carcinoma: Biological rationale and first results in early phase clinical trials. Cancers, 13.","DOI":"10.3390\/cancers13020271"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fphar.2014.00254","article-title":"Improving the safety of cell therapy products by suicide gene transfer","volume":"5","author":"Jones","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Whilding, L., Halim, L., Draper, B., Parente-Pereira, A., Zabinski, T., Davies, D., and Maher, J. (2019). CAR T-Cells Targeting the Integrin \u03b1v\u03b26 and co-expressing the chemokine receptor cxcr2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers, 11.","DOI":"10.3390\/cancers11050674"},{"key":"ref_114","unstructured":"(2017). Tisagenlecleucel (kymriah) for all. Med. Lett. Drugs Ther., 59, 177\u2013178."},{"key":"ref_115","unstructured":"(2018). Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma. Med. Lett. Drugs Ther., 60, e122\u2013e123."},{"key":"ref_116","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2798\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:24:31Z","timestamp":1760138671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":116,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112798"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112798","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742188511.793593617","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,4]]}}}